Nuclear Verdicts Drive Rising US Liability Claims
Five key liability claim trends, including the rise of nuclear verdicts and the use of artificial intelligence in legal processes, are set to significantly impact businesses and insurers, reshaping the risk landscape, according to a report by Alllianz Commercial.
“As technology and the world evolve, the insurance market faces a number of new challenges which are leading to increasing liability loss trends,” stated Alfredo Alonso, global head of liability insurance at Allianz Commercial. “These increasing loss trends are influencing insurers’ perspectives on issues such as capacity deployment, especially in the U.S., and the profitability of both older and future underwriting years. Collaboration among stakeholders is crucial to managing these changes and controlling liability claims costs.”
The number one trend is the surge in so-called “nuclear verdicts” – jury awards exceeding $10 million — in the United States in recent years. Even more concerning is the rise of “thermonuclear verdicts,” which surpass the $100 million mark. According to research by Marathon Strategies, 2023 saw a 27% increase in the number of nuclear verdicts against companies over 2022, while thermonuclear verdicts jumped by 35%, the report noted.
Several factors are driving this trend. Growing mistrust of corporations, erosion of tort reform, and changes in jury pool demographics have all contributed to the proliferation of these outsized awards. Additionally, the normalization of large verdicts has shifted public perception of what constitutes appropriate compensation. Plaintiff attorneys have also honed their tactics, employing psychological strategies such as “reptile theory” – which aims to incite fear and anger in jurors – and “anchoring” – a technique that establishes an unreasonably high award amount in jurors’ minds, Allianz Commercial reported.
The impact of these nuclear verdicts on the insurance industry and businesses has been profound, according to the report. Over the past decade, liability claims in the U.S. have surged by 57%, largely due to these enormous jury awards. In 2023 alone, U.S. commercial casualty insurance losses totaled $143 billion – significantly higher than the $108 billion cost of global natural catastrophes in the same year.
Certain insurance lines are bearing the brunt of this trend. Commercial general liability, auto, and product liability have been hit particularly hard, with loss severity in these areas far outpacing economic inflation. For instance, the average loss severity increase for product liability over the 10-year period leading up to 2023 was 20.4%, compared to an average annual economic inflation rate of just 2.7%.
Efforts to address this issue are underway, albeit with mixed results, per the report. Some states have implemented tort reform measures to limit the size and scope of verdicts. Florida, historically the second-ranking state for nuclear verdicts, saw a notable decrease in 2023, with the sum of nuclear verdicts falling to $492 million. However, other states have moved in the opposite direction, expanding liability in wrongful death cases.
Arne Holzheuer, global practice group head for liability in the chief claims office at Allianz Commercial, offers a sobering perspective on the situation: “The only way is up when it comes to awards in the U.S. Attorneys continue to find new ways to bring cases in front of plaintiff friendly juries in so-called ‘judicial hell holes’, where most insureds are minded to settle, rather than risk a nuclear verdict from a jury trial. But this then sets a high benchmark for all the other plaintiffs that are in waiting.”
Pharma Class Actions
The pharmaceutical and chemical industries are facing a growing wave of billion-dollar class action lawsuits, with recent high-profile cases setting new precedents. Johnson & Johnson’s proposed $6.5 billion settlement for over 50,000 cases alleging cancer-causing talc products exemplifies the scale of these legal challenges. Similarly, Monsanto has reportedly reached settlement agreements in nearly 100,000 weedkiller-related lawsuits, valued at approximately $11 billion.
These cases highlight a concerning trend for the industry: a single harmful product or ingredient can spark multiple actions across numerous producers. For instance, at least four major manufacturers of ranitidine-based heartburn products are currently facing tens of thousands of cases in the U.S. over cancer allegations.
“It’s just the commercial reality of the pharmaceuticals sector – when a drug becomes a top seller, generic manufacturers market it alongside the brand manufacturer and if there is a problem, they all get pulled into class action litigation,” Holzheuer said.
PFAS Litigation
Another emerging trend with potentially far-reaching consequences is litigation surrounding per- and polyfluoroalkyl substances (PFAS). These synthetic chemicals, used extensively in industrial and consumer products since the 1940s, are now at the center of what some experts predict could become the next asbestos-level litigation crisis.
PFAS, often called “forever chemicals” due to their persistence in the environment, have been used in a wide range of products, from food packaging and cosmetics to firefighting foams and fabric treatments. However, scientific studies have linked PFAS exposure to various health issues, including increased cancer risk and damage to the immune system.
As awareness of these health risks grows, Allianz Commercial reported that litigation is focusing on three main areas: environmental pollution, water and waste treatment contamination, and personal injury actions. The latter currently centers on individuals working directly with PFAS products, such as firefighters.
The potential scale of PFAS litigation is staggering, with some estimates suggesting it could exceed $100 billion. Recent settlements by major PFAS producers have already reached significant sums, including a $10.3 billion settlement with public utilities in 2023.
Larry Crotser, head of key case management, North America at Allianz Commercial, notes, “Personal injury litigation is ongoing for those plaintiffs, often firefighters, who allege that certain cancers are caused by long term exposure to firefighting foam containing PFAS, but it’s too early to say with total confidence if PFAS bodily injury litigation will spill over significantly into the wider population.”
Growth of European Collection Actions
Europe is witnessing a significant surge in class action litigation. In 2023, a record-breaking 133 class actions were filed across the continent, marking a 10% increase from the previous year. This trend is particularly pronounced in the United Kingdom, Netherlands, Germany, and Portugal, which collectively accounted for 78% of all European class actions.
The UK, Europe’s largest market for class actions, saw the total claimed value of such lawsuits rise by 18% to €145 billion in 2023. Product liability, consumer issues, and personal injury cases emerged as the primary drivers, representing nearly a third of all class actions in the region.
This uptick in collective actions can be attributed, in part, to recent legislative changes in the European Union. The EU’s Representative Actions Directive, which came into force in December 2020, mandates that member states allow qualified entities, such as consumer organizations or public authorities, to bring collective actions on behalf of consumers and, in some cases, small businesses.
Additionally, an upcoming overhaul of the EU Product Liability Directive is set to expand the scope of liability and simplify the process for consumers to initiate legal action.
AI’s Influence on the Legal Profession
As the legal landscape evolves, artificial intelligence is playing an increasingly significant role in shaping the future of law practice.
AI tools are now being employed to automate various legal processes, including contract drafting, judgment preparation, legal research, and analytics. A survey by Thomson Reuters reveals that 70% of legal professionals anticipate AI and generative AI will have a transformational or high impact on the legal profession within the next five years, the report noted.
Leading law firms are already embracing this technological shift. In 2023, Allen & Overy launched an AI-powered platform to assist its lawyers in day-to-day legal work, covering areas such as contract analysis, due diligence, litigation, and regulatory compliance.
The influence of AI extends beyond streamlining legal processes; it has the potential to significantly impact the volume and nature of future class action litigation.
“AI could be used by the plaintiff’s bar and litigation funders, for example, to find emerging trends – such as trawling regulatory and scientific papers to find a new chemical classified as carcinogenic – as well make it faster and cheaper to administer class action litigation,” stated Peter Dowling, group head – personal injury and class actions at Allianz Commercial.
View the full report here. &